Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 3:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 3,537 matching trials from the live ClinicalTrials.gov search.
Completed Phase 3 Interventional Results available

EZN-2279 in Patients With ADA-SCID

NCT01420627
Conditions
ADA-SCID, Adenosine Deaminase Deficiency, Severe Combined Immunodeficiency
Interventions
EZN-2279, Adagen
Biological
Lead sponsor
Leadiant Biosciences, Inc.
Industry
Eligibility
Not listed
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 3 more
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 99 Years
Enrollment
1,310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
47
States / cities
Anchorage, Alaska • Little Rock, Arkansas • Long Beach, California + 41 more
Conditions
Pregnancy Complications, Cardiovascular
Interventions
Purely observational study on the care and outcomes of participants with cardiovascular disease in pregnancy.
Other
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
18 Years and older · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Kansas City, Missouri
Recruiting Not applicable Interventional Accepts healthy volunteers

The Function of Biphasic Sleep in Infants

NCT06399939
Conditions
Sleep Deprivation
Interventions
Nap, Wake
Behavioral
Lead sponsor
University of Massachusetts, Amherst
Other
Eligibility
9 Months to 15 Months
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
Amherst, Massachusetts
Conditions
Bronchopulmonary Dysplasia
Interventions
Lung Ultrasound
Diagnostic Test
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
0 Days and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Herpes Simplex Virus
Interventions
Novel Antiviral Drug, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Day to 98 Days
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
18
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 15 more
Terminated Not applicable Interventional

Feeding Study in VLBW Premature Infants

NCT05744193
Conditions
VLBW - Very Low Birth Weight Infant
Interventions
Exempt Infant Formula
Other
Lead sponsor
Mead Johnson Nutrition
Industry
Eligibility
168 Days to 224 Days
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
Birmingham, Alabama • Augusta, Georgia • Indianapolis, Indiana + 3 more
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

The Pharmacokinetics of Ketamine in the Breast Milk of Lactating Women

NCT04285684
Conditions
Ketamine, Lactation
Interventions
ketamine in lactation
Drug
Lead sponsor
The Ketamine Research Foundation
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
San Anselmo, California
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Early Limited Formula Use on Breastfeeding Outcomes

NCT00952328
Conditions
Breastfeeding
Interventions
Nutramigen infant formula
Dietary Supplement
Lead sponsor
University of California, San Francisco
Other
Eligibility
24 Hours to 48 Hours
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
San Francisco, California
Conditions
Cystic Fibrosis
Interventions
ELX/TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
46
States / cities
Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 42 more
Conditions
Post-Hemorrhagic Hydrocephalus
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
Up to 180 Days
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
6
States / cities
Birmingham, Alabama • St Louis, Missouri • Pittsburgh, Pennsylvania + 3 more
Conditions
Infant Lumbar Puncture
Interventions
Simulation-based mastery learning
Other
Lead sponsor
Columbia University
Other
Eligibility
24 Years to 40 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Conditions
Erosive Esophagitis, Heartburn, Symptomatic Non-erosive Gastroesophageal Reflux Disease, Helicobacter Pylori Infection
Interventions
Vonoprazan
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
15 Years to 50 Years · Female only
Enrollment
728 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
Wilmington, North Carolina
Conditions
Fanconi Anemia, Inherited Bone Marrow Failure Syndrome
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
8 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Serious Systemic Infections, Necrotizing Enterocolitis
Interventions
Metronidazole
Drug
Lead sponsor
Michael Cohen-Wolkowiez
Other
Eligibility
Up to 90 Days
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
3
States / cities
Orange, California • Wichita, Kansas • Durham, North Carolina
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Ichthyosis, Autosomal Recessive Congenital Ichthyosis, Lamellar Ichthyosis, Congenital Ichthyosiform Erythroderma, Epidermolytic Ichthyosis, Netherton Syndrome
Interventions
Secukinumab, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Conditions
Late-Onset Neonatal Sepsis, Extreme Prematurity, Neonatal Hypotension
Interventions
Dopamine, Norepinephrine
Drug
Lead sponsor
Mount Sinai Hospital, Canada
Other
Eligibility
21 Weeks to 32 Weeks
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Phoenix, Arizona • Dayton, Ohio • San Antonio, Texas
Conditions
MPS II, Hunter Syndrome (MPS II)
Interventions
RGX-121-3102
Genetic
Lead sponsor
REGENXBIO Inc.
Industry
Eligibility
4 Months to 5 Years · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
New Brunswick, New Jersey
Completed No phase listed Observational Accepts healthy volunteers

Ontogeny of Measles Immunity in Infants

NCT00240916
Conditions
Measles
Interventions
Attenuvax (Measles Virus Live Vaccine, 0.5ml subcutaneous), MMR-II (Measles-Mumps-Rubella Virus Live Vaccine, 0.5ml subcutaneous)
Biological
Lead sponsor
Stanford University
Other
Eligibility
6 Months and older
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1993 – 2013
U.S. locations
2
States / cities
Palo Alto, California • Stanford, California
Conditions
Cystic Fibrosis
Interventions
Lumacaftor, Ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years to 11 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
19
States / cities
Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 16 more
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Electroencephalography
Interventions
Not listed
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 72 Hours
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
8
States / cities
Palo Alto, California • Atlanta, Georgia • Detroit, Michigan + 4 more
Conditions
Prediction of Extubation Readiness
Interventions
Cardiorespiratory signal acquisition
Other
Lead sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Other
Eligibility
Not listed
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Detroit, Michigan • Providence, Rhode Island
Completed No phase listed Observational Results available

Perinatal Stroke: Understanding Brain Reorganization

NCT02743728
Conditions
Stroke, Hemiparesis
Interventions
Magnetic Resonance Imaging, Transcranial Magnetic Stimulation, General Movement Assessment
Device · Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
3 Months to 5 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota